Results 171 to 180 of about 43,486 (267)

Safety and Efficacy of Glucagon‐Like Peptide‐1 Receptor Agonists Use in Elderly People With Obesity—A Meta‐Analysis

Obesity, EarlyView.
ABSTRACT Objective This meta‐analysis evaluates the safety and efficacy of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) for the treatment of older adults with obesity compared to younger individuals. Methods A systematic review was conducted following PRISMA guidelines (PROSPERO CRD420251074381).
Inês Rego de Figueiredo, Filipa Sofia Simas, Angela Ghiletchi, João Oliveira Torres, José Silva‐Nunes   +4 more
wiley   +1 more source

Tirzepatide Regulates Pacemaker Function by Modulating cAMP and Calcium Dynamics in Human Sinoatrial Node Cells. [PDF]

Circulation
Ren L, Belbachir N, Zhang H, Thai PN, Huang R, Zhu W, Wu X, Xie M, Gao J, Kim HY, Liu T, Sun J, Ghazizadeh Z, Navedo MF, Wu JC.   +14 more
europepmc   +1 more source

Evaluating the Evolving Real‐World Adverse Events of GLP‐1RAs Using FDA Adverse Event Reporting System (FAERS)

Obesity, EarlyView.
Web portal for interrogating Adverse Events of GLP‐1 RA in diabetes vs weight control/obesity. ABSTRACT Objective This study aimed to assess the spectrum and frequency of adverse events (AEs) linked to glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) using the US FDA Adverse Event Reporting System (FAERS).
David Stone, Mary Playdon, Stephen D. Hursting, Aik Choon Tan   +3 more
wiley   +1 more source

Potential of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Mitigating Metabolic Side Effects Associated With Clozapine or Olanzapine Therapy: A Literature Review. [PDF]

Cureus
Meftah A, Yoade B, Cowart C, Choi A, Popoola O, Afe O, Efremoff S, Ezema C, Johnson B, Lawrence J, Olupona T.   +10 more
europepmc   +1 more source

Responses to GLP‐1RA in White and Black Adults With Obesity: Insights From Generalized Additive Mixed Models of EHR Data

Obesity, EarlyView.
ABSTRACT Objective This study examined racial differences in weight loss and clinical response to glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) therapy among adults with obesity using real‐world data. Methods We retrospectively analyzed our institution's Research Data Warehouse (RDW) containing deidentified data from electronic health records ...
Jordan H. Mallette, Joshua S. Speed, Seth T. Lirette, Daniel Moore, John S. Clemmer   +4 more
wiley   +1 more source

eNAMPT induces alpha-cell mass expansion but impaired glucagon counter regulatory response.

Endocrinology
Sayers SR, Gesheva VS, Varghese JJ, Beavil R, Zhao M, Cheah Y, Hopkins D, Fine NHF, Hasib A, Hodson DJ, Caton PW.   +10 more
europepmc   +1 more source

Cutaneous Allodynia Associated With GLP-1RA Tirzepatide for Weight Management: A Case Series. [PDF]

Am J Case Rep
Chakrabarti MP, Han S, Campbell NM.
europepmc   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonist‐Based Agents and Body Composition: Filling More Gaps

Obesity, EarlyView.
ABSTRACT The last 2 decades have seen historic advances in the treatment of obesity. We are entering an era of defining obesity not by weight‐based outcomes but by changes in body composition. Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are forming the platform for obesity treatments based on their high level of efficacy. Body composition can
Robert L. Dubin, Tierra N. Sanders, Hunter M. Schwab, Steven B. Heymsfield, Frank L. Greenway   +4 more
wiley   +1 more source

GLP-1 Receptor Agonists in Neurological Disorders: From Mechanisms to Clinical Translation. [PDF]

Drug Des Devel Ther
Li P, Gao Y, Liu W.
europepmc   +1 more source

Glucagon receptor (GCGR) [PDF]

Science-Business eXchange, 2009
openaire   +1 more source